BC Week In Review | Apr 13, 2009
Clinical News

AVN-101: Phase I started

Avineuro began an open-label, placebo-controlled, Russian Phase I trial to evaluate oral AVN-101 in 16 healthy volunteers. Avineuro Pharmaceuticals Inc. , San Diego, Calif.   Product: AVN-101   Business: Neurology   Molecular target: Serotonin (5-HT) receptor...
Items per page:
1 - 1 of 1